These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ; Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663 [TBL] [Abstract][Full Text] [Related]
5. Utilizing pharmacodynamic properties of second-generation antipsychotics to guide treatment. Schwartz T; Bedynerman K Drugs Today (Barc); 2012 Apr; 48(4):283-92. PubMed ID: 22536570 [TBL] [Abstract][Full Text] [Related]
6. Asenapine: a clinical review of a second-generation antipsychotic. Stoner SC; Pace HA Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521 [TBL] [Abstract][Full Text] [Related]
8. Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group. De Fazio P; Girardi P; Maina G; Mauri MC; Mauri M; Monteleone P; Perini GI; Perugi G; Rossi A Clin Drug Investig; 2010; 30(12):827-841. PubMed ID: 20923242 [TBL] [Abstract][Full Text] [Related]
9. Antipsychotic agents: efficacy and safety in schizophrenia. de Araújo AN; de Sena EP; de Oliveira IR; Juruena MF Drug Healthc Patient Saf; 2012; 4():173-80. PubMed ID: 23236256 [TBL] [Abstract][Full Text] [Related]
10. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165 [TBL] [Abstract][Full Text] [Related]
11. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Citrome L Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150 [TBL] [Abstract][Full Text] [Related]
12. Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population. Hartung DM; Middleton L; McFarland BH; Haxby DG; McDonagh MS; McConnell KJ Psychiatr Serv; 2013 Dec; 64(12):1236-42. PubMed ID: 23999754 [TBL] [Abstract][Full Text] [Related]
13. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Smith RC; Leucht S; Davis JM Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237 [TBL] [Abstract][Full Text] [Related]
14. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. Samalin L; Ben Gharbia M; Garnier M; Llorca PM Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735 [TBL] [Abstract][Full Text] [Related]
15. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
16. EPS profiles: the atypical antipsychotics are not all the same. Weiden PJ J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588 [TBL] [Abstract][Full Text] [Related]
17. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review]. Munch G; Godart N Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720 [TBL] [Abstract][Full Text] [Related]
18. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Barbui C; Nosè M; Mazzi MA; Thornicroft G; Schene A; Becker T; Bindman J; Leese M; Helm H; Koeter M; Weinmann S; Tansella M Int Clin Psychopharmacol; 2006 Nov; 21(6):355-62. PubMed ID: 17012982 [TBL] [Abstract][Full Text] [Related]
19. Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. Kim DD; Barr AM; Chung Y; Yuen JWY; Etminan M; Carleton BC; White RF; Honer WG; Procyshyn RM CNS Drugs; 2018 Oct; 32(10):917-938. PubMed ID: 30121819 [TBL] [Abstract][Full Text] [Related]
20. Lurasidone in the treatment of schizophrenia: a critical evaluation. Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]